JP2025510603A - トリアジン化合物、中間体、製造方法および用途 - Google Patents

トリアジン化合物、中間体、製造方法および用途 Download PDF

Info

Publication number
JP2025510603A
JP2025510603A JP2024554171A JP2024554171A JP2025510603A JP 2025510603 A JP2025510603 A JP 2025510603A JP 2024554171 A JP2024554171 A JP 2024554171A JP 2024554171 A JP2024554171 A JP 2024554171A JP 2025510603 A JP2025510603 A JP 2025510603A
Authority
JP
Japan
Prior art keywords
hydrogen
methyl
alkyl group
formula
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510603A5 (enExample
Inventor
沈孝坤
黄金文
Original Assignee
湖北九康通生物医▲薬▼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 湖北九康通生物医▲薬▼有限公司 filed Critical 湖北九康通生物医▲薬▼有限公司
Publication of JP2025510603A publication Critical patent/JP2025510603A/ja
Publication of JP2025510603A5 publication Critical patent/JP2025510603A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2024554171A 2022-03-10 2023-03-10 トリアジン化合物、中間体、製造方法および用途 Pending JP2025510603A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202210245736 2022-03-10
CN202210245736.X 2022-03-10
CN202210557410 2022-05-20
CN202210557410.0 2022-05-20
PCT/CN2023/080920 WO2023169572A1 (zh) 2022-03-10 2023-03-10 一种三嗪类化合物、其中间体、其制备方法及其用途

Publications (2)

Publication Number Publication Date
JP2025510603A true JP2025510603A (ja) 2025-04-15
JP2025510603A5 JP2025510603A5 (enExample) 2026-03-10

Family

ID=87905051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554171A Pending JP2025510603A (ja) 2022-03-10 2023-03-10 トリアジン化合物、中間体、製造方法および用途

Country Status (8)

Country Link
US (1) US20250188102A1 (enExample)
EP (1) EP4491623A4 (enExample)
JP (1) JP2025510603A (enExample)
KR (1) KR20250002216A (enExample)
CN (1) CN116730988A (enExample)
AU (1) AU2023231321A1 (enExample)
CA (1) CA3248484A1 (enExample)
WO (1) WO2023169572A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
CN116284133B (zh) * 2022-03-24 2024-03-29 南京知和医药科技有限公司 一种新型六元杂环类衍生物及其药物组合物和用途
CN116514784A (zh) * 2022-04-01 2023-08-01 深圳安泰维生物医药有限公司 一种三嗪类化合物及其用途
KR20250046274A (ko) 2022-08-05 2025-04-02 길리애드 사이언시즈, 인코포레이티드 SARS-CoV2 주요 프로테아제 억제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604595T3 (pl) * 2010-08-10 2016-09-30 Pochodna triazyny i związek farmaceutyczny, który ją zawiera i wykazuje aktywność przeciwbólową
CN114539228A (zh) * 2022-03-14 2022-05-27 药康众拓(江苏)医药科技有限公司 三嗪类化合物或其可药用盐、异构体、药物组合物和用途
CN114507221B (zh) * 2022-04-21 2022-08-26 药康众拓(江苏)医药科技有限公司 一种三嗪类化合物及其在制备抗病毒药物上的用途
CN114790198B (zh) * 2022-06-24 2022-10-04 药康众拓(江苏)医药科技有限公司 一种三嗪类化合物及其制备方法和应用
CN116496266A (zh) * 2022-07-08 2023-07-28 歌礼生物科技（杭州）有限公司 三嗪衍生物

Also Published As

Publication number Publication date
KR20250002216A (ko) 2025-01-07
CN116730988A (zh) 2023-09-12
AU2023231321A1 (en) 2024-10-31
EP4491623A1 (en) 2025-01-15
US20250188102A1 (en) 2025-06-12
EP4491623A4 (en) 2026-03-18
WO2023169572A1 (zh) 2023-09-14
CA3248484A1 (en) 2025-07-07

Similar Documents

Publication Publication Date Title
JP6666263B2 (ja) グルタミナーゼの新規阻害剤
EP2253625B1 (en) Pyridazinones, the preparation and the use thereof
CN107922354B (zh) 作为idh2抑制剂的杂环化合物
WO2023169572A1 (zh) 一种三嗪类化合物、其中间体、其制备方法及其用途
WO2023042879A1 (ja) ウイルス増殖阻害活性を有する二環性複素環誘導体およびそれらを含有する医薬組成物
KR20240004634A (ko) 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
Yang et al. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension
US11344553B2 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
TW202340190A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制劑及其用途
CN107325067A (zh) 磷酸二酯酶4抑制剂桑辛素m衍生物及其用途
US10173995B2 (en) Pyridine compounds used as PI3 kinase inhibitors
TWI614251B (zh) 具抑制細菌葡萄醣醛酸酶活性之吡唑並［４，３－ｃ］喹啉衍生物
CN111662275A (zh) 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
CN102133217B (zh) 一类以n为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途
TW202219047A (zh) 靶向gpr35之治療劑
CN117120423B (zh) 吲哚胺2,3-双加氧酶抑制剂、其制备方法及包含其的药物组合物
JP2003523952A (ja) 新規な３−ニトロピリジン誘導体及び該誘導体を含む製薬組成物
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物
CN121202878A (zh) 一种c-Met抑制剂及其制备方法和应用
CN109280028A (zh) 喹啉类化合物及其在dpp-4酶抑制剂的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260220